p e r s p e c t i v e
Human pluripotent stem cells (PSCs) are a leading candidate for cell-based therapies because of their capacity for unlimited self renewal and pluripotent differentiation. These advances have recently culminated in the first-in-human PSC clinical trials by Geron, Advanced Cell Technology and the Kobe Center for Developmental Biology for the treatment of spinal cord injury and macular degeneration. Despite their therapeutic promise, a crucial hurdle for the clinical implementation of human PSCs is their potential to form tumors in vivo. In this Perspective, we present an overview of the mechanisms underlying the tumorigenic risk of human PSC-based therapies and discuss current advances in addressing these challenges.
PSCs, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), offer immense potential as a source for regenerative therapies, as was recently recognized by the 2012 Nobel Committee in Medicine. However, the intrinsic qualities of self renewal and pluripotency that make these cells so therapeutically promising are also responsible for an equally fundamental tumorigenic potential. In this regard, PSC tumorigenicity can ultimately be divided into two separate categories: malignant transformation of differentiated PSCs and benign teratoma formation from residual undifferentiated PSCs, which can produce tumors consisting of one or all three germ layers, respectively 1 .
The risks of PSC tumorigenicity have been highlighted over the past several years in a number of small and large animal studies, including preclinical dose-escalation tests for the first-in-human PSC clinical trial to be approved by the US Food and Drug Administration in 2009. In this case, mice that received the Geron human ESC-derived neural progenitor cell product GRNOPC1 developed cysts in regenerating tissue sites of the spine, prompting a 1-year moratorium on the trial even before the first patient received treatment 2 . Other animal studies using ESC-and iPSC-based therapies have shown further risk for PSC tumorigenic potential 3 . These include the development of neural overgrowths and tumors from human ESC-derived dopaminergic neurons and neural progenitor cells transplanted into small animals and ocular tumors in mice that received ESC-derived retinal progenitors [4] [5] [6] . Moving one step further into primate models, human ESC-derived dopaminergic neurons transplanted into the brains of Parkinsonian monkeys have also resulted in the formation of tumors 7 . Although PSC-derived tumors have yet to be reported in humans, several case studies have documented the formation of tumors in patients receiving fetal or adult stem cell treatments. For example, tumors developed in the brain of a 12-year-old boy who received fetal neural stem cell transplantation for treatment of ataxia telangiectasia 8 and in the kidney of a 46-year-old woman who received autologous hematopoietic stem cell transplantation for treatment of lupus nephritis 9 .
The introduction of PSC derivatives to the clinic by the now defunct Geron trial 10 , by Advanced Cell Technology (ACT) 11 and by the Center for Developmental Biology in Kobe 12 risks the development of PSC-derived tumors in patients. On one side is the promise of a new era for regenerative medicine, and on the other side is the risk of iatrogenic tumors, an occurrence that would certainly slow progress in this field. In this Perspective, we discuss the hurdles to clinical implementation of PSCs that are associated with tumorigenicity and review current advances in addressing these challenges.
Conserved gene expression networks between cancers and PSCs
Gene expression networks that are responsible for the maintenance and induction of pluripotency in PSCs are interconnected and in many cases share components with the networks implicated in oncogenesis. Fundamental to both networks are genes that confer high proliferation capacity, self renewal, DNA repair checkpoint uncoupling and/or the ability to differentiate into multifaceted tissues. Such oncogenic properties are so central to PSC identity that teratoma formation is a gold standard for the experimental demonstration of pluripotency in human PSCs. Of particular importance are the MYC transcription factor and core pluripotency networks (that is, NANOG, OCT4 and SOX2), which have emerged as fundamental gene circuits shared by PSCs and cancers 13, 14 . Both of these transcriptional networks function to promote self renewal, proliferation and multipotency. However, the activity of oncogenic transcription networks in PSCs should not be considered as the sole domain of undifferentiated cells, as recent studies have demonstrated that differentiated cells may also retain or even reactivate such networks 13, 14 . Narva et al. 15 found that almost half of the genes (>44%) that are transcriptionally upregulated as a result of genomic aberrations present in human ESCs are functionally linked to the expression of cancer genes. As a result, PSCs and their tumorigenic progeny show hallmarks of cancer, including a lack of contact inhibition in vitro, loss of p53-and RB-mediated regulation of the cell cycle and resistance to apoptosis 1 .
Although it is difficult to predict what threshold of oncogenic gene activation results in tumor propagation, numerous groups have begun to qualitatively and quantitatively compare PSCs and cancers using large database-driven analyses. In this regard, Ben-Porath et al. 13 described a correlation between more aggressive cancers and the expression of the core pluripotency and Myc-centered networks. Conversely, the expression of polycomb genes related to cell differentiation has been associated with decreased cancer aggression. Kim et al. 14 analyzed transcriptional networks by using a stringent in vivo biotinylation technique to probe protein-protein and protein-DNA interactions. This approach indicated that the MYC transcriptional network has a central role in both cancers and PSCs. These analyses have provided insights into the identity and function of such gene networks and have elucidated their relationships to the global transcriptional networks that are necessary for pluripotency and oncogenesis. Moving forward, we believe that such bioinformatics screens should be viewed as hypothesis generating and should prompt additional studies to elucidate the functional consequences of the genetic expression profiles shared by cancers and PSCs. Because of the general lack of such studies and, even more fundamentally, the lack of an objective scoring system to quantify the results from such studies, it is difficult to determine at what exact threshold the expression of these genes involved in pluripotency and cancer becomes of clinical concern.
There has been considerable work done in investigating the role of pluripotency gene networks in cancer. For example, Cui et al. 16 found that the well-studied stem cell signaling pathway WNT is a strong determinant of tumor formation from ESC-derived retinal progenitor cells 6 . Much of this work has focused on MYC and its effectors. The risks of the MYC oncogene are probably best highlighted in iPSC derivation. To this end, reactivation of genomically integrated MYC in donor cells has been shown to produce somatic tumors in chimeric mice generated from iPSCs 17, 18 . Although MYC has since been found to be dispensable for reprogramming 19 , the close association of this network with the fundamental core pluripotency factors suggests that internetwork crosstalk activates MYC, or at least its effectors. The juxtaposition of the MYC and core pluripotency networks is further supported in a recent study by Lin et al. 20 showing that MYC-mediated tumorigenesis occurs in PSCs through the transcriptional amplification of oncogenic gene expression programs that are inherent to PSC identity. These reports have established MYC as a central player in oncogenesis and pluripotency, the ectopic activation of which has been linked definitively to somatic tumor formation 13, 14 .
In addition to the MYC network, other core pluripotency factors underlying ESC and iPSC identity have also been shown to promote cancer development. Ectopic activation of OCT4 in somatic cells, for example, induces dysplastic development and features of malignancy 21 . A number of studies have highlighted the inter-related nature of pluripotency and oncogenic gene networks in promoting adult somatic cancers. For example, Lee et al. 22 showed that NANOG has a role in the self renewal of CD24 + cancer stem cells in hepatocellular carcinoma. SOX2 has been shown to drive cancer-cell survival and oncogenic fate in several cancer types, including squamous cell carcinomas of the lung and esophagus 23 . KLF-4 has been reported to promote DNA repair checkpoint uncoupling and cellular proliferation in breast cancers by p53 suppression 24 . Thus, it is apparent that transcription factors that are associated with pluripotency drive the oncogenesis of not only PSC-derived teratomas but also clinical adult malignancies. This is evidenced in preclinical animal studies in which the inappropriate expression of pluripotency genes in transplanted PSC derivatives results in single-germ-layer tumors, such as proliferating neural rosettes and ocular tumors, instead of the threegerm-layer tumors that are typical of teratoma formation 4-7 .
The aberrant activation of both MYC and OCT4 has also been noted in 'partially' reprogrammed colonies in which inadequate silencing or reactivation of these genes results in a 'pseudo-pluripotent' state that shows high levels of proliferation and resistance to differentiation 25 . It is difficult to assess the temporal sequence of events, for example, whether OCT4 activates MYC or whether the resultant tumorigenic cell properties are due directly to a cascade of more established oncogenic networks that are triggered by the initial ectopic expression of one or more pluripotency transgenes. As the evidence mounts that suggests a role for the inappropriate regulation of MYC and OCT4 in PSC tumorigenesis, it will be crucial to further study the expression of core pluripotency factors and their relationships with established oncogenic networks to ensure patient safety.
Tumorigenicity associated with iPSC reprogramming
The recent derivation of iPSCs from somatic tissues by the ectopic expression of core pluripotency factors raises additional concerns for the tumorigenic potential of PSCs (Box 1). Compared to their ESC counterparts, iPSCs are exposed to a number of factors that could promote oncogenic transformation, including genomic insertion of reprogramming vectors, overexpression of oncogenic transcription factors and a global hypomethylation resembling that seen in cancers (Fig. 1) . Although functional studies that directly compare iPSC and ESC tumorigenicity are currently lacking, numerous reports have highlighted the oncogenic risks associated with the induction of pluripotency 1, 18, 19 .
Strategies to diminish the tumorigenic transformation of iPSCs have focused primarily on a variety of gene delivery vectors that minimize genomic disruption ( Table 1) . These methods can be divided generally into two categories: integrating vectors that can be excised from the host genome and nonintegrating vectors. Proof of principle for the derivation of iPSCs using excisable vectors was demonstrated by Soldner et al. 26 , who used a doxycycline-inducible lentiviral construct flanked by loxP sites, which allowed for excision of the construct by Cre recombinase. Because Cre recombinase-driven excision leaves residual loxP sequences at sites of integration that could disrupt genomic coding or activate oncogenic promoters, Woltjen et al. 27 followed this study by deriving iPSCs using integrating transposons that could be subsequently excised by piggyBac transposition. Unlike Cre 
recombinase, the use of transposon-based excision leaves no genomic traces and allows for the xeno-free production of iPSCs. However, piggyBac transposition carries the risk of uncontrolled cycles of excision and integration, increasing the possibility of nonconservative deletions within coding regions of the genome.
Nonintegrating techniques for iPSC generation, such as epichromosomal viruses and plasmids, have also been investigated as a means to circumvent the integration and reactivation of potentially oncogenic reprogramming factors. These methodologies are generally considered to be safer than excisable integration techniques, as they avoid even temporary genomic modifications. However, standard nonintegrating strategies such as those using adenoviruses suffer from extremely low transduction efficiencies (0.001%) and, in the case of episomal plasmids, require the use of potent oncogenes such as the SV40LT antigen for the induction of pluripotency 28, 29 . Recent efforts have thus focused on the identification of new and more efficient vectors such as minicircle vectors 30 and the Sendai virus 31 , which is an RNA virus lacking a DNA phase that therefore has no risk of genomic integration. The major disadvantage of the Sendai virus-mediated approach is that the virus is known to replicate continuously in the cytoplasm, producing reprogramming transgenes that may not be silenced adequately.
A number of studies have reprogrammed somatic cells by the direct delivery of synthetic mRNAs or pluripotency proteins or the transfection of mature microRNAs [32] [33] [34] . The primary advantages of these techniques are the virtual elimination of risk of integration and the ability to engineer controlled transgene expression. However, reprogramming efficiency is difficult to maintain, requiring frequent transfections for prolonged periods of time. In addition, considerable technical skills are required to carry out this type of reprogramming, and only a handful of centers have been able to successfully apply these strategies.
Several recent studies have reported the successful elimination of MYC from reprogramming cocktails 19 . These strategies improve the safety of iPSC generation at the expense of efficiency. Substitution of c-MYC with L-MYC has been shown to be a viable method to retain higher reprogramming efficiencies without the risk of MYCinduced oncogenesis 35 . Another strategy to avoid the use of MYC or other transcription factors while maintaining reprogramming efficiency is the use of small molecules 36 . However, small molecules have off-target effects that are capable of inducing oncogenesis, many of which have yet to be fully elucidated. Until the ramifications of these compounds are better understood, the clinical applicability of this approach is unclear.
The induction of pluripotency has itself also been linked to tumorigenic transformation by creating genomic aberrations at the chromosomal and subchromosomal levels (Fig. 2) . Laurent et al. 37 conducted the first study that compared the high-resolution SNP profiles of ESC, iPSC, somatic stem cell and primary adult cell lines. Importantly, the authors found numerous deletions of tumor-suppressor genes in iPSCs immediately after the induction of pluripotency that were absent from the somatic cells of origin. Hussein et al. 38 reported similar findings by using high-resolution SNP arrays to compare copy number variations in early and late passage iPSCs with their somatic cells of origin. The authors suggested that replication stress associated with the reprogramming process is responsible for the de novo mutations that arise during the induction of pluripotency, indicating that the process of demethylation itself results in genomic structural instability. Another potential mechanism for how demethylation could produce such lesions is by facilitating access to proto-oncogenes by the transcriptional machinery. Global hypomethylation has been shown to exist in both PSCs and cancers 39 . Chromosome-remodeling factors that facilitate reprogramming through demethylation have been associated with somatic tumors and cancer stem cells by their activation of previously silenced oncogenes 40 . Aberrant methylation has also been linked to the insufficient inactivation or reactivation of pluripotency transgenes, leading to tumor development through the induction of genomic lesions secondary to hasty and error-prone replication 39 . Several reports have also demonstrated that genomic hypomethylation alone is sufficient to induce chromosomal translocations that result in tumorigenesis. Seminal work in this area has been by conducted by the Jaenisch laboratory, which showed that the induction of a hypomorphic allele of DNA methyltransferase 1 (DNMT1) results in genomes with only 10% methylation, thereby facilitating loss of heterozygosity in oncogenic neurofibromatosis and p53 genes 41 . Such lesions may be due to the fact that methylation offers a level of structural genetic stability, and its removal therefore promotes genomic instability. As the induction of pluripotency produces global hypomethylation, it is necessary to understand the respective oncogenic contributions of the reprogramming process compared with other potential causes of PSC tumorigenicity, such as culture adaptation.
Impact of culture adaptation on ESCs and iPSCs
In addition to the tumorigenic risks inherent to the induction of pluripotency, culture adaptation is another prevalent mechanism that is known to activate oncogenic networks. In this regard, current models of cell therapy can require hundreds of millions to billions of cells per patient 42 . The development of scalable cell-culture methods to achieve these numbers is a high priority and will probably require substantial periods of in vitro expansion. It is important to note that the PSC state is analogous to the inner cell mass, a highly transitory stage of development that is not meant for indefinite propagation. It is therefore not surprising that chromosome instability is naturally prevalent in early embryos, a fact that becomes apparent when embryos are artificially selected and implanted during in vitro fertilization 43 . In addition, several recent studies have demonstrated that developmentally immature PSCs show deficient DNA damage repair and cell-cycle arrest 44 . Although PSCs may respond to DNA damage and replicative stress through apoptosis, a minority of cells do not and continue to proliferate even after sustaining genetic lesions 45 . As a result, prolonged PSC culture produces genomic abnormalities, including chromosomal aneuploidy, translocations, mega-scale duplications and deletions, and point mutations 46 . Although the generation of such genetic lesions is stochastic, their accumulation is not. Subclones that gain selective growth advantages due to either loss of tumor suppressor genes or gain of proliferation genes will outcompete others in vitro. The net result is the propagation of cultures that have steadily and heterogeneously acquired tumorigenic potential.
The effect of culture adaptation is most noticeable in the accumulation of gross chromosomal abnormalities in high-passage PSCs. Draper et al. 47 were the first to specifically characterize such genomic lesions and showed that prolonged ESC culture produces recurrent gains of chromosomes 17q and 12. This work has been followed by others who continually expand the list of recurrent genetic lesions in PSCs 48, 49 . Taking this work one step further, Mayshar et al. 46 compared the genomic integrity of human ESCs and iPSCs to demonstrate that many of the genetic abnormalities found in ESCs and germ-cell cancers are duplicated in iPSCs as a result of culture adaptation. Notably, these changes include copy number gains in chromosome 12p, which contains the pluripotency transcription factor Nanog and numerous growth and survival genes such as Stellar and GDF3. Expanding this analysis to 38 international laboratories, the International Stem Cell Initiative (ISCI) recently completed the largest survey of PSC genetic variability, comparing 125 human ESC and 11 iPSC lines 50 . This study found karyotype abnormalities in 34% of the lines tested, with more than 20% harboring a conserved 20q11.12 mutation that conferred increased activity of the anti-apoptotic gene BCL2L1 (ref. 50) . Ultimately, these genetic modifications have profound functional implications, promoting tumorigenic qualities such as increased proliferation, growth factor independence, niche autonomy and higher frequencies of tumor-initiating cells 51 .
The fact that such genetic lesions are generated stochastically suggests that substantial variations can arise between the PSCs generated 
in different laboratories and even between subclones from the same cell lines. Indeed, comparisons of identical cell lines grown in different laboratories demonstrate that disparate culture conditions can result in long-term, laboratory-specific gene expression profiles 52 . These results highlight the impact of culture conditions on PSC gene expression. An explanation for such variations can be inferred from work by Narsinh et al. 53 that demonstrates significant cell-to-cell variability within the same PSC colony, implying that there is considerable plasticity in the pluripotent state. These findings highlight the need for stringent enforcement of in vitro culture and maintenance standards across PSC types, lines and laboratory-specific subclones to ensure patient safety.
Teratomas, immunogenicity and tumor-removal strategies
The potential of PSCs and their differentiated progeny to form tumors after transplantation is one of the largest hurdles for clinical entry. To this end, one of the major factors influencing oncogenic development is the immune recognition of both differentiated and undifferentiated PSCs 54, 55 . On one hand, a high level of immune function would prevent tumor formation to the extent that the entire graft would be rejected. On the other hand, reduced immunogenicity would facilitate cell engraftment but also allow for tumor formation in the event of aberrant donor cell behavior. In this regard, two categories of PSC grafts exist that have disparate immunogenic properties: autologous (self-derived) and allogeneic (donor-derived) cell transplantations. One of the primary appeals of iPSC development is the potential to create autologous grafts that evade immune rejection. Although substantial debate exists within this field 56 , the current evidence supports the hypothesis that autologous iPSC-derived grafts are not strongly immunogenic. Recent work by Araki et al. 57 and Guha et al. 58 used syngeneic mouse models to demonstrate that transplanted iPSC-derived embryoid bodies, skin and bone marrow tissues engraft efficiently with almost no signs of rejection. Such immune evasion is desirable, as it obviates the need for the harsh immunosuppressive regimens that are required by conventional allogeneic transplant strategies. However, it is important to note that an immune-privileged status may be potentially shared by aberrant cells existing within the graft and could facilitate the development of tumors derived from host tissue.
Although iPSCs may reach the clinic as early as late 2013 (ref. 12), clinical trials using ESC derivatives began in earnest from 2010 (refs. 10,11) . ESC-derived grafts are fundamentally different from iPSC-derived grafts in that ESCs are derived from the excess blastocysts discarded by in vitro fertilization clinics and hence can only be transplanted allogeneically. Drukker et al. 59 were the first to characterize ESC immunogenicity and showed decreased major histocompatibility complex (MHC) expression in undifferentiated PSCs compared to their differentiated progeny. Such a trend is problematic, as undifferentiated cells would be less susceptible to immune recognition compared to the therapeutic cell types that are derived from these cells. Further complicating this picture is the interplay of other cellular immune effectors apart from T cells, namely natural killer cells, which recognize cells that have decreased MHC expression 60 . As such, further study into the complex interplay of the immune system must be undertaken before we can fully understand PSC immunogenicity. However, it is probable that because differentiation results in the increased expression of markers that can be recognized by the immune system, any allogeneic PSC-derived graft would be likely to require some degree of immune suppression 61, 62 . Therefore, a balance between tumorigenicity and immunogenicity must be achieved. Such a balance will probably require a tailored approach that depends on the patient population, delivery site and/or therapeutic product 63 . The prospective removal (for example, before transplantation) of tumorigenic cells is preferable to retrospective cancer treatments, as prospective methods would provide the highest level of patient safety while reducing the need for post-transplantation surveillance. Prospective removal is achieved optimally by using intrinsic cell properties such as surface antigens. These techniques include antibody-induced cytotoxicity 64 and fluorescent activated cell sorting (FACS) or magnetic activated cell sorting (MACS) depletion based on pluripotencyassociated surface markers 65 or enrichment based on surface markers that are associated with differentiation 66 . The key to any such technique is the identification or insertion of markers or cellular traits that change drastically after PSC differentiation. Such a trait was highlighted in a recent paper by Ben-David et al. 67 , which identified a new metabolic pathway that is inherent to the survival of undifferentiated cells. By developing a small-molecule inhibitor of stearoylCoA desaturase, a key enzyme in this pathway, the authors were able to selectively eliminate undifferentiated PSCs from culture. Although these strategies are promising for teratoma prevention, further studies must be conducted to ensure that the proposed methods of PSC depletion do not inadvertently hinder the engraftment of therapeutic cell types or more subtly interfere with graft integration, function or long-term survival. Ideally, the most stringent safety regimes would utilize a flexible, combinatorial approach that may require tailoring for specific PSC lines or graft types. Should these techniques fail to adequately remove enough residual PSCs, retrospective tumor treatments may also be used, including oncologic chemotherapy, radiation and surgery 68 or the incorporation of suicide ablation genes 69 .
In addition to removing residual undifferentiated cells, attention should also be given to the removal of genetically abnormal cells independently of their differentiation status. Although little work has been done in this area, Herszfeld et al. 70 provided the first evidence that CD30 expression is correlated with genetic abnormalities. Such a cell-surface target provides a convenient marker for FACS-or MACSbased separation and highlights the fact that we must first fully understand the most common and most clinically relevant genetic lesions before we can confidently ensure the removal of genetically aberrant PSCs and their derivatives. Ultimately, the risks of tumor formation from undifferentiated PSCs should be considered a substantial but surmountable hurdle that requires careful study of PSC biology so that we can develop the necessary stringent manufacturing practices and high levels of quality control.
Conclusion
More than therapeutic efficacy, risks to patient safety are a primary focus in phase 1 clinical trials that often dictate the opinions of both the scientific community and the lay public. In this regard, tumorigenicity is a potential hurdle that could halt ESC and iPSC research. It is therefore imperative that researchers thoroughly and systematically investigate the factors influencing PSC tumor formation before proceeding with large-scale clinical implementation. Notably, although we describe a number of key contributors to tumorigenicity, their relative importance in producing a clinical phenotype is unknown and requires further investigation. Preclinical studies conducted by researchers in both industry and academia have demonstrated that tumor formation from PSC-derived therapies is a distinct possibility, with reported developments of cystic structures, primitive tissue grafts and teratomas in animal models [3] [4] [5] [6] .
Looking ahead, the next major test for PSC safety lies in the results of the first-in-human PSC-based clinical trials initiated by Geron 10 , ACT 11 and the Kobe Center for Developmental Biology 12 . Thus far, these trials have enrolled a total of 15 known patients. Five of these patients received Geron's oligodendrocyte progenitor cell therapy (GRNOPC1) in the setting of acute spinal cord injury before the closure of this trial. An additional ten patients received PSC-derived retinal pigment epithelial cells for Stargardt's macular dystrophy as part of the first phase of ACT's phase 1/2 trial. Preliminary reports on two patients from the ACT trial have been reported by Schwartz et al. 11 , who noted no tumor formation or signs of rejection within the first 4 months of transplantation. Moving forward, plans are underway to begin the first iPSC clinical trial in Japan, which aims to treat six patients with age-related macular degeneration using iPSC-derived retinal epithelial cells 12 . Caveats to these first PSC trials are that the cell numbers used are several orders of magnitude lower than those used in adult stem cell clinical trials, which are typically hundreds of millions to billions of cells. In addition, tests to monitor graft survival are limited, so the absence of tumor formation in patients may be potentially attributed to a failure of donor cells to engraft. As more human trials are approved and patient data are generated, our understanding of the tumorigenic potential of PSC-based therapies will continue to evolve.
As our knowledge of PSC biology develops, especially with improved methods to generate these cells and their differentiated progeny, it is probable that additional factors influencing tumorigenicity will emerge. Because PSCs are derived and maintained using artificial techniques, the biology of these cells deviates substantially from their natural in vivo environment, the inner cell mass. It is therefore not surprising that troubling oncologic lesions and phenotypes develop with our often relatively crude manipulations. Our duty as PSC biologists and clinicians should be to thoroughly understand these cells of our own creation before we move PSC-based therapies to the patient bedside.
